Egetis Therapeutics Logo

Egetis Therapeutics

Develops and commercializes drugs for serious rare diseases with unmet medical needs.

EGTX | ST

Overview

Corporate Details

ISIN(s):
SE0003815604
LEI:
549300RZCKGWRUBPMY22
Country:
Sweden
Address:
Klara Norra Kyrkogata 26, 111 22 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious, rare diseases with significant unmet medical needs. The company's strategy centers on advancing projects through late-stage clinical development to regulatory approval and market launch. Its leading drug candidate, Emcitate, targets MCT8 deficiency, a rare genetic disease characterized by a shortage of thyroid hormones in the brain.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Change in the number of shares and votes in Egetis Therapeutics
English 58.2 KB
2025-10-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Egetis Therapeutics
Swedish 61.4 KB
2025-10-23 08:00
Legal Proceedings Report
Egetis beviljas löpande NDA-granskning av FDA för Emcitate® (tiratricol) basera…
Swedish 90.0 KB
2025-10-23 08:00
Regulatory News Service
Egetis granted a rolling NDA review by FDA for Emcitate® (tiratricol) based on …
English 86.3 KB
2025-10-02 23:40
Share Issue/Capital Change
Egetis Therapeutics has successfully carried out a directed share issue amounti…
English 82.9 KB
2025-10-02 23:40
Share Issue/Capital Change
Egetis Therapeutics har framgångsrikt genomfört en riktad nyemission uppgående …
Swedish 83.7 KB
2025-10-02 17:31
Share Issue/Capital Change
Egetis Therapeutics intends to carry out a directed share issue of up to 10 per…
English 76.8 KB
2025-10-02 17:31
Share Issue/Capital Change
Egetis Therapeutics avser att genomföra en riktad nyemission av högst 10 procen…
Swedish 78.4 KB
2025-08-21 07:00
Interim Report
Swedish 3.7 MB
2025-08-21 07:00
Interim Report
English 3.4 MB
2025-07-15 08:00
Regulatory News Service
Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 de…
English 75.2 KB
2025-07-15 08:00
Legal Proceedings Report
Egetis erhåller Breakthrough Therapy Designation från FDA för tiratricol för be…
Swedish 71.1 KB
2025-05-16 00:00
Annual Report (ESEF)
Swedish 12.4 MB
2025-05-06 17:59
Post-Annual General Meeting Information
Kommuniké från Egetis Therapeutics årsstämma 2025
Swedish 55.3 KB
2025-05-06 17:59
Post-Annual General Meeting Information
Bulletin from Egetis Therapeutics’ Annual General Meeting 2025
English 52.3 KB

Automate Your Workflow. Get a real-time feed of all Egetis Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Egetis Therapeutics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Egetis Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-09 Yilmaz Mahshid Other Sell 39,753 268,332.75 SEK
2025-01-08 Yilmaz Mahshid Other Sell 98,567 653,499.21 SEK
2025-01-07 Yilmaz Mahshid Other Sell 74,769 507,681.51 SEK
2024-10-07 Nicklas Westerholm Other Buy 10,142 43,103.50 SEK
2024-10-07 Yilmaz Mahshid Other Buy 10,000 42,250.00 SEK
2023-07-07 Henrik Krook Other Buy 33,594 133,704.12 SEK
2023-07-06 Christian Sonesson Other Buy 3,616 14,391.68 SEK
2023-07-06 Christian Sonesson Other Buy 2,000 7,920.00 SEK
2023-07-05 Christian Sonesson Other Buy 1,384 5,452.96 SEK
2023-07-04 Nicklas Westerholm Other Buy 15,350 60,632.50 SEK

Peer Companies

Company Country Ticker View
Canopy Growth Corp Logo
Produces diverse cannabis products for medical and recreational markets globally.
United States of America CGC
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany HIGH
CAPRICOR THERAPEUTICS, INC. Logo
Develops cell and exosome-based therapeutics for rare diseases like Duchenne muscular dystrophy.
United States of America CAPR
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea 214370
Caribou Biosciences, Inc. Logo
Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.
United States of America CRBU
Carisma Therapeutics Inc. Logo
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
United States of America CARM
Cartesian Therapeutics, Inc. Logo
Pioneering mRNA-engineered cell therapies to treat autoimmune diseases.
United States of America RNAC
CASI Pharmaceuticals, Inc. Logo
Develops and commercializes drugs for oncology, transplant, and autoimmune disease.
United States of America CASI
CASSAVA SCIENCES INC Logo
Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.
United States of America SAVA
CATALYST PHARMACEUTICALS, INC. Logo
Advancing therapies for rare neuromuscular and neurological diseases like LEMS.
United States of America CPRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.